{"id":892342,"date":"2025-10-03T16:04:32","date_gmt":"2025-10-03T20:04:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/"},"modified":"2025-10-03T16:04:32","modified_gmt":"2025-10-03T20:04:32","slug":"forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/","title":{"rendered":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules"},"content":{"rendered":"

<\/p>\n

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules<\/b><\/p>\n

DALLAS–(BUSINESS WIRE<\/a>)–
\nForte Biosciences, Inc. (www.fortebiorx.com<\/a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.<\/p>\n

\nIn accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 125,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting employment with the Company. The option awards shall vest over four years, with twenty-five percent vesting on the one-year anniversary of the applicable optionee\u2019s employment commencement date and the remaining seventy-five percent vesting in approximately equal monthly increments over the succeeding thirty-six months, subject to the individual\u2019s continuous employment through each vesting date.<\/p>\n

\nThe Inducement Awards were made under Forte\u2019s 2020 Inducement Equity Incentive Plan and related award agreements.<\/p>\n

About Forte<\/b><\/p>\n

\nForte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.<\/p>\n

\nSource: Forte Biosciences, Inc.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251003067466\/en\/<\/a><\/span><\/p>\n

\nForte Biosciences, Inc.
\n
Paul Wagner, CEO
\n
investors@fortebiorx.com<\/a><\/p>\n

\nLifeSci Advisors
\n
Mike Moyer, Managing Director
\n
mmoyer@lifesciadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> Texas United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules DALLAS–(BUSINESS WIRE)– Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 125,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting employment with the Company. The option awards shall vest over four years, with twenty-five percent vesting on the one-year anniversary of the applicable optionee\u2019s employment commencement date and … <\/p>\n

Continue reading “Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892342","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules DALLAS–(BUSINESS WIRE)– Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 125,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting employment with the Company. The option awards shall vest over four years, with twenty-five percent vesting on the one-year anniversary of the applicable optionee\u2019s employment commencement date and … Continue reading "Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-03T20:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules\",\"datePublished\":\"2025-10-03T20:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/\"},\"wordCount\":254,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/\",\"name\":\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-10-03T20:04:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/","og_locale":"en_US","og_type":"article","og_title":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk","og_description":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules DALLAS–(BUSINESS WIRE)– Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 125,000 shares of common stock to new non-executive employees as a material inducement to such individuals accepting employment with the Company. The option awards shall vest over four years, with twenty-five percent vesting on the one-year anniversary of the applicable optionee\u2019s employment commencement date and … Continue reading \"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-03T20:04:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules","datePublished":"2025-10-03T20:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/"},"wordCount":254,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/","name":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-10-03T20:04:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251003067466r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892342"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892342\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}